poisar

Stocks · News reference

Opus Genetics shares are trading higher after the company announced plans to present topline clinical data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 in investor webcast and upcoming Ophthalmology conferences.

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IRD
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

    Opus Genetics announced plans to present topline clinical data from Phase 1/2 Cohort 1 of its OPGx-BEST1 gene therapy program during an investor conference call on September 9, 2026. The company will also present full clinical datasets and additional analyses at several upcoming ophthalmology conferences including Euretina, Retina in Rio, and FLORetina.

    IRD